Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 6-7/2017

01-10-2017 | Research Paper

Neurosurgical management of brain metastases

Authors: Sherise D. Ferguson, Kathryn M. Wagner, Sujit S. Prabhu, Mary F. McAleer, Ian E. McCutcheon, Raymond Sawaya

Published in: Clinical & Experimental Metastasis | Issue 6-7/2017

Login to get access

Abstract

Brain metastases present a significant public health issue, affecting more than 100,000 patients per year in the U.S. and result in significant morbidity. Brain metastases can occur in a variety of clinical situations ranging from multiple brain metastases with uncontrolled systemic disease to a solitary metastasis in the setting of controlled systemic disease. Additionally, advances in genomics have broadened the opportunities for targeted treatment options and potentially more durable systemic responses. As such, the treatment of brain metastases is now more tailored and multimodal, involving systemic, radiation, and surgical therapies, often in combination. This review discusses the historical and current role of neurosurgical techniques in the treatment of brain metastases.
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics, 2008. CA 58(2):71–96PubMed
2.
Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G (2011) Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 22(1):1–6, vCrossRefPubMed
3.
4.
Brastianos PK, Curry WT, Oh KS (2013) Clinical discussion and review of the management of brain metastases. J Natl Compr Cancer Netw 11(9):1153–1164CrossRef
5.
Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK (2011) The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8(6):344–356PubMedPubMedCentral
6.
Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B (2016) Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol 127(3):407–414CrossRefPubMed
7.
Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500CrossRefPubMed
8.
Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33(6):583–590CrossRefPubMed
9.
Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17):1485–1489CrossRefPubMed
10.
Nieder C, Astner ST, Grosu AL, Andratschke NH, Molls M (2007) The role of postoperative radiotherapy after resection of a single brain metastasis. Combined analysis of 643 patients. Strahlenther Onkol 183(10):576–580CrossRefPubMed
11.
Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S et al (2007) Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68(5):1388–1395CrossRefPubMed
12.
Tallet AV, Azria D, Barlesi F, Spano JP, Carpentier AF, Goncalves A et al (2012) Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 7(1):77CrossRefPubMedPubMedCentral
13.
Tendulkar RD, Liu SW, Barnett GH, Vogelbaum MA, Toms SA, Jin T et al (2006) RPA classification has prognostic significance for surgically resected single brain metastasis. Int J Radiat Oncol Biol Phys 66(3):810–817CrossRefPubMed
14.
Lee CH, Kim DG, Kim JW, Han JH, Kim YH, Park CK et al (2013) The role of surgical resection in the management of brain metastasis: a 17-year longitudinal study. Acta Neurochir (Wien) 155(3):389–397CrossRef
15.
Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW (2005) Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery 56(5):1021–1034PubMed
16.
Sperduto CM, Watanabe Y, Mullan J, Hood T, Dyste G, Watts C et al (2008) A validation study of a new prognostic index for patients with brain metastases: the graded prognostic assessment. J Neurosurg 109(Suppl):87–89PubMed
17.
Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70(2):510–514CrossRefPubMed
18.
Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 77(3):655–61CrossRefPubMed
19.
Karnofsky DA, Abelmann WH, Craver LS, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma. Cancer 1(4):634–656CrossRef
20.
Baumert BG, Rutten I, Dehing-Oberije C, Twijnstra A, Dirx MJ, Debougnoux-Huppertz RM et al (2006) A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys 66(1):187–194CrossRefPubMed
21.
Kamp MA, Dibue M, Niemann L, Reichelt DC, Felsberg J, Steiger HJ et al (2012) Proof of principle: supramarginal resection of cerebral metastases in eloquent brain areas. Acta Neurochir (Wien) 154(11):1981–1986CrossRef
22.
Yoo H, Kim YZ, Nam BH, Shin SH, Yang HS, Lee JS et al (2009) Reduced local recurrence of a single brain metastasis through microscopic total resection. J Neurosurg 110(4):730–736CrossRefPubMed
23.
Patel AJ, Suki D, Hatiboglu MA, Rao VY, Fox BD, Sawaya R (2015) Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis. J Neurosurg 122(5):1132–1143CrossRefPubMed
24.
Patel AJ, Suki D, Hatiboglu MA, Abouassi H, Shi W, Wildrick DM et al (2010) Factors influencing the risk of local recurrence after resection of a single brain metastasis. J Neurosurg 113(2):181–189CrossRefPubMed
25.
Suki D, Abouassi H, Patel AJ, Sawaya R, Weinberg JS, Groves MD (2008) Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 108(2):248–257CrossRefPubMed
26.
Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA et al (2013) Invasion patterns in brain metastases of solid cancers. Neuro Oncol 15(12):1664–1672CrossRefPubMedPubMedCentral
27.
Siam L, Bleckmann A, Chaung HN, Mohr A, Klemm F, Barrantes-Freer A et al (2015) The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study. Oncotarget 6(30):29254–29267CrossRefPubMedPubMedCentral
28.
Kamp MA, Rapp M, Slotty PJ, Turowski B, Sadat H, Smuga M et al (2015) Incidence of local in-brain progression after supramarginal resection of cerebral metastases. Acta Neurochir (Wien) 157(6):905–910 (discussion 10–11)CrossRef
29.
Sanmillan JL, Fernandez-Coello A, Fernandez-Conejero I, Plans G, Gabarros A (2016) Functional approach using intraoperative brain mapping and neurophysiological monitoring for the surgical treatment of brain metastases in the central region. J Neurosurg 2016:1–10CrossRef
30.
Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC et al (2005) The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 63(1):37–46CrossRefPubMed
31.
Hasegawa T, Kondziolka D, Flickinger JC, Germanwala A, Lunsford LD (2003) Brain metastases treated with radiosurgery alone: an alternative to whole brain radiotherapy? Neurosurgery 52(6):1318–1326CrossRefPubMed
32.
Selek U, Chang EL, Hassenbusch SJ 3rd, Shiu AS, Lang FF, Allen P et al (2004) Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59(4):1097–1106CrossRefPubMed
33.
Trifiletti DM, Lee CC, Winardi W, Patel NV, Yen CP, Larner JM et al (2015) Brainstem metastases treated with stereotactic radiosurgery: safety, efficacy, and dose response. J Neurooncol 125(2):385–392CrossRefPubMed
34.
Trifiletti DM, Lee CC, Kano H, Cohen J, Janopaul-Naylor J, Alonso-Basanta M et al (2016) Stereotactic radiosurgery for brainstem metastases: an international cooperative study to define response and toxicity. Int J Radiat Oncol Biol Phys 96(2):280–288CrossRefPubMedPubMedCentral
35.
Mathieu D, Kondziolka D, Flickinger JC, Fortin D, Kenny B, Michaud K et al (2008) Tumor bed radiosurgery after resection of cerebral metastases. Neurosurgery 62(4):817–823 (discussion 23–24)CrossRefPubMed
36.
Jagannathan J, Yen CP, Ray DK, Schlesinger D, Oskouian RJ, Pouratian N et al (2009) Gamma Knife radiosurgery to the surgical cavity following resection of brain metastases. J Neurosurg 111(3):431–438CrossRefPubMed
37.
Jensen CA, Chan MD, McCoy TP, Bourland JD, deGuzman AF, Ellis TL et al (2011) Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg 114(6):1585–1591CrossRefPubMed
38.
Choi CY, Chang SD, Gibbs IC, Adler JR, Harsh GRT, Lieberson RE et al (2012) Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol 84(2):336–42
39.
Robbins JR, Ryu S, Kalkanis S, Cogan C, Rock J, Movsas B et al (2012) Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis. Neurosurgery 71(5):937–943CrossRefPubMed
40.
Atalar B, Modlin LA, Choi CY, Adler JR, Gibbs IC, Chang SD et al (2013) Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 87(4):713–718CrossRefPubMed
41.
Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, Yamada Y et al (2014) A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys 88(1):130–136CrossRefPubMed
42.
Ojerholm E, Lee JY, Thawani JP, Miller D, O’Rourke DM, Dorsey JF et al (2014) Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis. J Neurosurg 121(Suppl):75–83PubMed
43.
Iorio-Morin C, Masson-Cote L, Ezahr Y, Blanchard J, Ebacher A, Mathieu D (2014) Early Gamma Knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control. J Neurosurg 121(Suppl):69–74PubMed
44.
Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P et al (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040–1048
45.
Asher AL, Burri SH, Wiggins WF, Kelly RP, Boltes MO, Mehrlich M et al (2014) A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence. Int J Radiat Oncol Biol Phys 88(4):899–906CrossRefPubMed
46.
Patel KR, Burri SH, Asher AL, Crocker IR, Fraser RW, Zhang C et al (2016) Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: a multi-institutional analysis. Neurosurgery 79(2):279–285CrossRefPubMed
47.
Schackert G, Schmiedel K, Lindner C, Leimert M, Kirsch M (2013) Surgery of recurrent brain metastases: retrospective analysis of 67 patients. Acta Neurochir (Wien) 155(10):1823–1832CrossRef
48.
Bindal RK, Sawaya R, Leavens ME, Lee JJ (1993) Surgical treatment of multiple brain metastases. J Neurosurg 79(2):210–216CrossRefPubMed
49.
Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044CrossRefPubMed
50.
Park SH, Hwang SK, Kang DH, Lee SH, Park J, Hwang JH et al (2009) Gamma knife radiosurgery for multiple brain metastases from lung cancer. J Clin Neurosci 16(5):626–629CrossRefPubMed
51.
Serizawa T, Iuchi T, Ono J, Saeki N, Osato K, Odaki M et al (2000) Gamma knife treatment for multiple metastatic brain tumors compared with whole-brain radiation therapy. J Neurosurg 93(Suppl 3):32–36PubMed
52.
Raldow AC, Chiang VL, Knisely JP, Yu JB (2013) Survival and intracranial control of patients with 5 or more brain metastases treated with gamma knife stereotactic radiosurgery. Am J Clin Oncol 36(5):486–490CrossRefPubMed
53.
Knoll MA, Oermann EK, Yang AI, Paydar I, Steinberger J, Collins B et al (2016) Survival of patients with multiple intracranial metastases treated with stereotactic radiosurgery: does the number of tumors matter? Am J Clin Oncol
54.
Papadatos-Pastos D, Banerji U (2011) Revisiting the role of molecular targeted therapies in patients with brain metastases. J Neurooncol 105(3):467–474CrossRefPubMed
55.
Caffo M, Barresi V, Caruso G, Cutugno M, La Fata G, Venza M et al (2013) Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci 14(1):2135–2174CrossRefPubMedPubMedCentral
56.
Bindal RK, Sawaya R, Leavens ME, Hess KR, Taylor SH (1995) Reoperation for recurrent metastatic brain tumors. J Neurosurg 83(4):600–604CrossRefPubMed
57.
Mensel B, Weigel C, Hosten N (2006) Laser-induced thermotherapy. Recent Results Cancer Res 167:69–75
58.
59.
Lagman C, Chung LK, Pelargos PE, Ung N, Bui TT, Lee SJ et al (2017) Laser neurosurgery: a systematic analysis of magnetic resonance-guided laser interstitial thermal therapies. J Clin Neurosci 36:20–26CrossRefPubMed
60.
Rahmathulla G, Recinos PF, Kamian K, Mohammadi AM, Ahluwalia MS, Barnett GH (2014) MRI-guided laser interstitial thermal therapy in neuro-oncology: a review of its current clinical applications. Int Soc Cell 87(2):67–82
61.
Medvid R, Ruiz A, Komotar RJ, Jagid JR, Ivan ME, Quencer RM et al (2015) Current applications of MRI-guided laser interstitial thermal therapy in the treatment of brain neoplasms and epilepsy: a radiologic and neurosurgical overview. Am J Neuroradiol 36(11):1998–2006CrossRefPubMed
62.
De Poorter J (1995) Noninvasive MRI thermometry with the proton resonance frequency method: study of susceptibility effects. Magnet Reson Med 34(3):359–367CrossRef
63.
Jethwa PR, Barrese JC, Gowda A, Shetty A, Danish SF (2012) Magnetic resonance thermometry-guided laser-induced thermal therapy for intracranial neoplasms: initial experience. Neurosurgery 71(1 Suppl Operative):133–144 (44–45)PubMed
64.
Hawasli AH, Kim AH, Dunn GP, Tran DD, Leuthardt EC (2014) Stereotactic laser ablation of high-grade gliomas. Neurosurg Focus 37(6):E1CrossRefPubMed
65.
Voigt JD, Barnett G (2016) The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible. Cost Effect Resour Alloc 14:6CrossRef
66.
Thomas JG, Rao G, Kew Y, Prabhu SS (2016) Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma. Neurosurg Focus 41(4):E12CrossRefPubMed
67.
Wright J, Chugh J, Wright CH, Alonso F, Hdeib A, Gittleman H et al (2016) Laser interstitial thermal therapy followed by minimal-access transsulcal resection for the treatment of large and difficult to access brain tumors. Neurosurg Focus 41(4):E14CrossRefPubMed
68.
Carpentier A, McNichols RJ, Stafford RJ, Itzcovitz J, Guichard JP, Reizine D et al (2008) Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors. Neurosurgery 63(1 Suppl 1):ONS21–ONS28 (discussion ONS8–ONS9)PubMed
69.
Carpentier A, McNichols RJ, Stafford RJ, Guichard JP, Reizine D, Delaloge S et al (2011) Laser thermal therapy: real-time MRI-guided and computer-controlled procedures for metastatic brain tumors. Lasers Surg Med 43(10):943–950CrossRefPubMed
70.
Hawasli AH, Ray WZ, Murphy RK, Dacey RG Jr, Leuthardt EC (2012) Magnetic resonance imaging-guided focused laser interstitial thermal therapy for subinsular metastatic adenocarcinoma: technical case report. Neurosurgery 70(2 Suppl Operative):332–337 (discussion 8)PubMed
71.
Rao MS, Hargreaves EL, Khan AJ, Haffty BG, Danish SF (2014) Magnetic resonance-guided laser ablation improves local control for postradiosurgery recurrence and/or radiation necrosis. Neurosurgery 74(6):658–667 (discussion 67)CrossRefPubMed
72.
Torres-Reveron J, Tomasiewicz HC, Shetty A, Amankulor NM, Chiang VL (2013) Stereotactic laser induced thermotherapy (LITT): a novel treatment for brain lesions regrowing after radiosurgery. J Neurooncol 113(3):495–503CrossRefPubMed
73.
Ali MA, Carroll KT, Rennert RC, Hamelin T, Chang L, Lemkuil BP et al (2016) Stereotactic laser ablation as treatment for brain metastases that recur after stereotactic radiosurgery: a multiinstitutional experience. Neurosurg Focus 41(4):E11CrossRefPubMed
74.
Rennert RC, Santiago-Dieppa DR, Figueroa J, Sanai N, Carter BS (2016) Future directions of operative neuro-oncology. J Neurooncol 130(2):377–382CrossRefPubMed
75.
Sadikov E, Bezjak A, Yi QL, Wells W, Dawson L, Millar BA et al (2007) Value of whole brain re-irradiation for brain metastases–single centre experience. Clin Oncol (R Coll Radiol) 19(7):532–538CrossRef
76.
Son CH, Jimenez R, Niemierko A, Loeffler JS, Oh KS, Shih HA (2012) Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys 82(2):e167–e172CrossRefPubMed
77.
Ozgen Z, Atasoy BM, Kefeli AU, Seker A, Dane F, Abacioglu U (2013) The benefit of whole brain reirradiation in patients with multiple brain metastases. Radiat Oncol 8:186CrossRefPubMedPubMedCentral
78.
Chao ST, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Neyman G et al (2008) Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy. Cancer 113(8):2198–2204CrossRefPubMed
79.
Caballero JA, Sneed PK, Lamborn KR, Ma L, Denduluri S, Nakamura JL et al (2012) Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy. Int J Radiat Oncol Biol Phys 83(1):303–309CrossRefPubMed
80.
McKay WH, McTyre ER, Okoukoni C, Alphonse-Sullivan NK, Ruiz J, Munley MT et al (2016) Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery. J Neurosurg 2016:1–9CrossRef
Metadata
Title
Neurosurgical management of brain metastases
Authors
Sherise D. Ferguson
Kathryn M. Wagner
Sujit S. Prabhu
Mary F. McAleer
Ian E. McCutcheon
Raymond Sawaya
Publication date
01-10-2017
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6-7/2017
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-017-9860-z

Other articles of this Issue 6-7/2017

Clinical & Experimental Metastasis 6-7/2017 Go to the issue

Review article

The role of the neural niche in brain metastasis

Research Paper

Radiobiology and radiotherapy of brain metastases

Research Paper

Current chemotherapeutic regimens for brain metastases treatment

Research Paper

Metabolic advantages and vulnerabilities in brain metastases

Research Paper

Collective invasion in ductal and lobular breast cancer associates with distant metastasis

Commentary

Historical perspectives on the biology of brain metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits